Phase II Clinical Trials in Europe

Turning promising clinical signals into validated proof of concept

Phase II clinical trials represent a critical stage in drug development. After initial safety has been established, these studies aim to evaluate therapeutic efficacy, refine dosing strategies and generate the clinical signals required to move toward larger confirmatory trials.

Because Phase II trials often determine whether a therapy will progress further in development, sponsors must combine strong scientific design with efficient operational execution.

Novellas Healthcare supports biotech and pharmaceutical companies in conducting Phase II clinical trials across Europe, helping sponsors generate reliable proof-of-concept data while maintaining full visibility and control over study execution.

The strategic importance of Phase II trials

Phase II studies are designed to answer key scientific and development questions:

Does the therapy demonstrate meaningful clinical activity?
What is the optimal dosing strategy?
Which patient populations are most likely to benefit?
What endpoints should be used in Phase III trials?

Operational delays, poor site selection or recruitment challenges at this stage can significantly impact development timelines and investment decisions.

Novellas Healthcare helps sponsors mitigate these risks by combining experienced clinical teams, strong European site networks and agile study management.

Why sponsors choose Europe for Phase II clinical trials

Europe offers access to experienced investigators, diverse patient populations and strong clinical research infrastructures.

For Phase II trials, this environment allows sponsors to:

• identify specialized investigators with disease expertise
• recruit patients in complex indications or rare diseases
• collaborate with leading academic centers
• generate high-quality clinical data recognized by global regulators

Our teams support sponsors in identifying the most appropriate European countries and sites for their studies.

Our Phase II clinical trial capabilities

Novellas Healthcare supports sponsors throughout the operational lifecycle of Phase II studies.

Study feasibility and site identification

Selecting experienced investigators is essential to ensure high-quality data and efficient patient recruitment.

Our teams conduct detailed feasibility assessments and leverage established site networks across Europe to identify investigators with proven performance in Phase II studies.

Regulatory and ethics submissions

We support the preparation and submission of clinical trial applications and ethics committee dossiers across European countries, ensuring regulatory compliance and efficient study startup.

Study management and monitoring

Our clinical teams provide hands-on study management and monitoring to ensure protocol adherence, patient safety and high-quality data collection.

Direct collaboration between sponsors and clinical teams ensures transparency throughout the study.

Patient recruitment strategy

Recruitment challenges are one of the most common causes of Phase II delays.

Our teams support recruitment strategies tailored to the indication and patient population, working closely with investigators and clinical sites to ensure efficient enrollment.

A smarter way to start your Phase II study

Free early feasibility assessment

Many sponsors launch a Phase II study without having a clear understanding of the operational landscape in Europe.

Before initiating a study, Novellas Healthcare offers sponsors an early feasibility assessment designed to identify the optimal study strategy.

This assessment helps answer key operational questions:

• Which European countries are most suitable for the indication?
• Which sites have experience with similar studies?
• What recruitment timelines can realistically be expected?
• What regulatory timelines should be anticipated?

This approach allows sponsors to make informed decisions before committing to full study execution.

Request a feasibility discussion with our clinical team

Therapeutic Areas of Expertise:

Oncology
Rare diseases
Infectious diseases
Neurology
Cardiovascular diseases
Specialty care

Preparing the transition to Phase III

Phase II studies play a decisive role in shaping the future clinical development strategy.

Reliable data generated during this stage informs Phase III study design, endpoint selection and regulatory discussions.

Novellas Healthcare supports sponsors not only in Phase II trials but throughout the broader clinical development pathway.

Explore our expertise in:

Phase I Clinical Trials

Phase III Clinical Trials

Phase IV and Real-World Studies

Preparing a clinical study in Europe?

Selecting the right CRO partner can significantly impact the success and timeline of a Phase II program.

If you are preparing a proof-of-concept study or evaluating European feasibility for your clinical program, our clinical experts would be happy to discuss your project.